Cobenfy: A Revolutionary Breakthrough in Schizophrenia Treatment

Cobenfy: A Revolutionary Breakthrough in Schizophrenia Treatment On December 3, 2024, the landscape of schizophrenia treatment witnessed a monumental shift with the FDA approval of Cobenfy, a novel medication combining xanomeline and trospium chloride. This marks the first major advancement in antipsychotic drugs since the establishment of traditional dopamine-receptor-targeting medications as the standard of care. […]